Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15886682 | 0.79 | CHEK1 (0.49) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL15995871 | 0.76 | CHEK1 (0.43) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL15886714 | 0.75 | CHEK1 (0.42) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL16154730 | 0.73 | CHEK1 (0.41) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL17403218 | 0.71 | CHEK1 (0.42) | CHEK1TDP1NOTUMPDE5APDE1A | |
| SCHEMBL17645969 | 0.69 | RAB9A (0.40) | CHEK1TDP1 | |
| SCHEMBL11088652 | 0.68 | CHEK1 (0.49) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL15875306 | 0.67 | CHEK1 (0.36) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL13579002 | 0.66 | PDE5A (0.44) | CHEK1NOTUMPDE5APDE1APDE1B | |
| SCHEMBL3435779 | 0.65 | SCN5A (0.48) | CHEK1NOTUMPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-9050344-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140221347-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | CHEK1 2174/4885TDP1 1208/4885NOTUM 1454/4885 |
| US-20140221347-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, FURIN | CHEK1 4098/4885TDP1 1898/4885NOTUM 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.